

BLAZE™ MICROCHIP SYSTEM FOR REAL-TIME CHARACTERIZATION OF INTACT BIOPHARMACEUTICALS



Intabio, Inc., Newark, CA

Type:
Small-Med Size Company

Participating Organizations:
Merck & Co., Inc., Genentech,
Bristol-Myers Squibb and MilliporeSigma



» *Lena Wu*

INDUSTRY NEED

Complexity of biologics create a need for ongoing product quality analysis that adds significant time and cost to drug development, thus taking longer to get products to market. On average development phase can take up to 15-20 years to commercialize.

SOLUTION

Reducing time and cost during testing to assure high quality product outputs are achieved could get drugs to patients faster. This NIIMBL project facilitated testing of Intabio's Blaze™ system with member company cells to validate efficiencies and improve market access.

OUTCOME

The result reflected a reduction in testing time over 30x that of traditional testing increasing testing capacity from 3-5 samples per month to 100 samples overnight at a cost of \$65/sample vs approximately \$23,000/sample. Time and cost savings could result in bringing drugs to market 1-3 years faster. Intabio was able to increase the number of Early Access Program companies from 2-3 prior to NIIMBL to 20 after joining NIIMBL.



Photos courtesy of Intabio

This project was developed with an award from the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) and financial assistance from the U.S. Department of Commerce, National Institute of Standards and Technology (70NANB17H002).

“As an SMM, NIIMBL has helped validate the need for our product in the market faster than we could have imagined. The NIIMBL community provided us access to leading Pharma companies and enabled us to accomplish the same validation and feedback that would normally have required a marketing group and months of work.”

